REPL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
REPL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Replimune Group's enterprise value is $14.01 Mil. Replimune Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-200.44 Mil. Therefore, Replimune Group's EV-to-EBITDA for today is -0.07.
The historical rank and industry rank for Replimune Group's EV-to-EBITDA or its related term are showing as below:
During the past 7 years, the highest EV-to-EBITDA of Replimune Group was 0.39. The lowest was -18.75. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-14), Replimune Group's stock price is $6.71. Replimune Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.160. Therefore, Replimune Group's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Replimune Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group Annual Data | ||||||||||||||||
Trend | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -11.31 | -4.76 | -12.85 | -3.88 | -2.86 |
Replimune Group Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -6.51 | -2.86 | -5.14 | -3.03 | -0.63 |
For the Biotechnology subindustry, Replimune Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Replimune Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Replimune Group's EV-to-EBITDA falls into.
Replimune Group's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 14.006 | / | -200.442 | |
= | -0.07 |
Replimune Group's current Enterprise Value is $14.01 Mil.
Replimune Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-200.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (NAS:REPL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Replimune Group's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 6.71 | / | -3.160 | |
= | At Loss |
Replimune Group's share price for today is $6.71.
Replimune Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Replimune Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Sarchi | officer: Chief Commercial Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Konstantinos Xynos | officer: Chief Medical Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Emily Luisa Hill | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Pamela Esposito | officer: Chief Business Officer | C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801 |
Sushil Patel | officer: Chief Commercial Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
Tanya Lewis | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459 |
Veleka Peeples-dyer | director | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Andrew Schwendenman | officer: Chief Accounting Officer | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801 |
Philip Astley-sparke | director, 10 percent owner, officer: Executive Chairman | C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801 |
Robert Coffin | director, 10 percent owner, officer: President and C.E.O. | C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801 |
Love Colin | 10 percent owner, officer: Chief Operating Officer | C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801 |
Jean M. Franchi | officer: Chief Financial Officer | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Omega Fund Iv Gp, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Jason P Rhodes | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By Value_Insider Value_Insider • 12-07-2022
By GuruFocus Research GuruFocus Editor • 05-19-2023
By Value_Insider Value_Insider • 11-23-2022
By Stock market mentor Stock market mentor • 01-04-2023
By Marketwired • 09-19-2023
By Marketwired • 07-20-2023
By Marketwired • 08-03-2023
By Marketwired • 09-19-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.